Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Change in Receivables (2024 - 2025)

Caris Life Sciences has reported Change in Receivables over the past 2 years, most recently at $91.0 million for Q4 2025.

  • Quarterly results put Change in Receivables at $91.0 million for Q4 2025, up 383.97% from a year ago — trailing twelve months through Dec 2025 was $83.7 million (changed N/A YoY), and the annual figure for FY2025 was $29.8 million, down 11.91%.
  • Change in Receivables for Q4 2025 was $91.0 million at Caris Life Sciences, up from -$24.2 million in the prior quarter.
  • Over the last five years, Change in Receivables for CAI hit a ceiling of $91.0 million in Q4 2025 and a floor of -$24.2 million in Q3 2025.